Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New Drugs.

Lana Gettman1

  • 1Harding University, Searcy, Arkansas.

The Senior Care Pharmacist
|August 28, 2021
PubMed
Summary
This summary is machine-generated.

Three new medications approved in 2021, including vericiguat, tepotinib, and tivozanib, offer new treatment options for older adults. These drugs represent significant advancements in geriatric pharmacotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing professional etiquette and networking skills in pharmacy students: Evaluation of an etiquette dinner program.

Currents in pharmacy teaching & learning·2026
Same author

Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer's Disease.

The Senior care pharmacist·2024
Same author

New Drugs: Faricimab-svoa (Vabysmo<sup>™</sup>) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti<sup>™</sup>) for Glaucoma and Ocular Hypertension.

The Senior care pharmacist·2023
Same author

New Drug: Tirzepatide (Mounjaro<sup>™</sup>).

The Senior care pharmacist·2023
Same author

New Drugs Update: Three Novel Treatments for SARS-CoV-2.

The Senior care pharmacist·2022
Same author

New Drugs Update: Finerenone, Difelikefalin, and Avacopan.

The Senior care pharmacist·2022

Area of Science:

  • Geriatric Medicine
  • Pharmacology
  • Drug Development

Background:

  • The aging population presents unique challenges in healthcare, necessitating specialized therapeutic approaches.
  • Advances in pharmaceutical research have led to the development of novel medications targeting age-related conditions.
  • The US Federal Drug Administration (FDA) approval process ensures the safety and efficacy of new drugs.

Purpose of the Study:

  • To describe three recently FDA-approved medications: vericiguat, tepotinib, and tivozanib.
  • To highlight the potential utility of these medications in older patient populations.
  • To provide an overview of their mechanisms of action and approved indications relevant to geriatrics.

Main Methods:

  • Review of FDA approval documentation for vericiguat, tepotinib, and tivozanib in 2021.

Related Experiment Videos

  • Analysis of clinical trial data focusing on efficacy and safety in older adults.
  • Synthesis of pharmacological profiles and therapeutic applications.

    • Main Results:

    • Vericiguat, tepotinib, and tivozanib received FDA approval in 2021.
    • These medications target specific conditions with potential benefits for elderly patients.
    • Initial data suggest a favorable safety profile for these agents in geriatric cohorts.

    Conclusions:

    • Vericiguat, tepotinib, and tivozanib represent important new pharmacologic options for older adults.
    • Their approval signifies progress in addressing unmet medical needs in geriatric populations.
    • Further research and clinical experience will continue to define their role in long-term geriatric care.